A combination of ligand SAR and receptor site-directed mutagenesis reveals requirements for antagonist activity at the melanocortin-3 receptor.

Bettina Proneth, Federico P. Portillo, Carrie Haskell-Luevano

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)319-320
Number of pages2
JournalAdvances in experimental medicine and biology
StatePublished - 2009

Bibliographical note

Funding Information:
The work was funded by the NIH RO1DK57080 grant.

Cite this